Patents by Inventor Yongjiang Chen
Yongjiang Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240067782Abstract: An aluminum borate whisker reinforced and toughened non-metallic matrix composite is provided, which specifically includes a non-metallic material reinforced and toughened with aluminum borate whiskers. The composite exhibits a higher bending strength and fracture toughness and a higher wear resistance. A method for preparing the composite is also provided. The method includes mixing the aluminum borate whiskers and the non-metallic material to form a mixture; and sintering the mixture by a vacuum hot press method, or molding the mixture.Type: ApplicationFiled: November 6, 2023Publication date: February 29, 2024Inventors: Yue Shi, Bi Jia, Jinliang Shi, Zhigang Zou, Yong Zhou, Yongjiang Di, Yin Liu, Huichao He, Rong Wang, Xueyi Wang, Hao Tian, Jun Zhu, Rui Tang, Xingyu Chen, Danxia Zhang
-
Patent number: 10150770Abstract: A crystal form I of a Janus Kinase (JAK) inhibitor (3aR,5s,6aS)—N-(3-methoxyl-1,2,4-thiadiazole-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidine-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-formamide bisulfate of formula (I) is provided. Also provided is a method of preparing the crystal form I of the JAK inhibitor of formula (I). The preparation method includes crystallizing any crystal form or amorphous compound solid of formula (I) in a single organic solvent to obtain the form I crystal. The crystal form I has excellent crystal stability and chemical stability. Additionally, the crystal solvent used to produce the crystal form I has low toxicity and a relatively low content of residual solvent, making the compound better suited for clinical treatment.Type: GrantFiled: September 9, 2015Date of Patent: December 11, 2018Assignee: Jiangsu Hengrui Medicine Co., Ltd.Inventors: Piaoyang Sun, Guaili Wu, Xiaohui Gao, Yongjiang Chen, Lingjia Shen
-
Publication number: 20180237438Abstract: A crystal form I of a Janus Kinase (JAK) inhibitor (3aR,5s,6aS)-N-(3-methoxyl-1,2,4-thiadiazole-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidine-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-formamide bisulfate of formula (I) is provided. Also provided is a method of preparing the crystal form I of the JAK inhibitor of formula (I). The preparation method includes crystallizing any crystal form or amorphous compound solid of formula (I) in a single organic solvent to obtain the form I crystal. The crystal form I has excellent crystal stability and chemical stability. Additionally, the crystal solvent used to produce the crystal form I has low toxicity and a relatively low content of residual solvent, making the compound better suited for clinical treatment.Type: ApplicationFiled: September 9, 2015Publication date: August 23, 2018Applicants: Jiangsu Hengrui Medicine Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.Inventors: Piaoyang SUN, Guaili WU, Xiaohui GAO, Yongjiang CHEN, Lingjia SHEN
-
Patent number: 10023577Abstract: A crystal form of JAK kinase inhibitor bisulfate and a preparation method thereof are provided. In particular, a type II crystal of (3aR,5s,6aS)—N-(3-methoxyl-1,2,4-thiadiazole-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidine-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-formamide bisulfate and a preparation method thereof are described. The preparation method includes steps of crystallizing any solid crystal form or amorphous compound of formula (I) in a single organic solvent or a mixed organic solvent to obtain a type II crystal form of the compound of formula (I). The type II crystal form of the compound of formula (I) obtained by the described methods has good crystal stability and chemical stability. In addition, the solvent used for crystallization has low toxicity and residue, which is better suited for use in clinical treatment.Type: GrantFiled: October 9, 2015Date of Patent: July 17, 2018Assignee: JIANGSU HENGRUI CO., LTD.Inventors: Piaoyang Sun, Guaili Wu, Quanliang Zhang, Yongjiang Chen, Lingjia Shen
-
Publication number: 20170313709Abstract: A crystal form of JAK kinase inhibitor bisulfate and a preparation method thereof are provided. In particular, a type II crystal of (3aR,5s,6aS)-N-(3-methoxyl-1,2,4-thiadiazole-5-yl)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidine-4-yl)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-formamide bisulfate and a preparation method thereof are described. The preparation method includes steps of crystallizing any solid crystal form or amorphous compound of formula (I) in a single organic solvent or a mixed organic solvent to obtain a type II crystal form of the compound of formula (I). The type II crystal form of the compound of formula (I) obtained by the described methods has good crystal stability and chemical stability. In addition, the solvent used for crystallization has low toxicity and residue, which is better suited for use in clinical treatment.Type: ApplicationFiled: October 9, 2015Publication date: November 2, 2017Inventors: Piaoyang SUN, Guaili WU, Quanliang ZHANG, Yongjiang CHEN, Lingjia SHEN
-
Patent number: 9309226Abstract: Provided are crystalline Form I of (R,E)-N-(4-(3-chloro-4-(pyridin-2-yl-methoxy)-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl)-3-(1-methylpyrrolidin-2-yl) propenamide dimaleate (called SHR1258 dimaleate for short), preparation methods thereof, and pharmaceutical compositions containing the same. The crystalline Form I of SHR1258 dimaleate has good crystal stability and chemical stability, and can be used in the preparation of medicaments for treating diseases related to EGFR receptor tyrosine kinase or HER-2 receptor tyrosine kinase.Type: GrantFiled: June 4, 2013Date of Patent: April 12, 2016Assignee: Jiangsu Hengrui Medicine Co., Ltd.Inventors: Piaoyang Sun, Guaili Wu, Bo Yuan, Yongjiang Chen
-
Publication number: 20150166511Abstract: Provided are crystalline Form I of (R,E)-N-(4-(3-chloro-4-(pyridin-2-yl -methoxy)-phenylamino)-3-cyano-7-ethoxy-quinolin-6-yl)-3-(1-methylpyrr olidin-2-yl) propenamide dimaleate (called SHR1258 dimaleate for short), preparation methods thereof, and pharmaceutical compositions containing the same. The crystalline Form I of SHR1258 dimaleate has good crystal stability and chemical stability, and can be used in the preparation of medicaments for treating diseases related to EGFR receptor tyrosine kinase or HER-2 receptor tyrosine kinase.Type: ApplicationFiled: June 4, 2013Publication date: June 18, 2015Applicant: JIANGSU HENGRUI MEDICINE CO., LTD.Inventors: Piaoyang Sun, Guaili Wu, Bo Yuan, Yongjiang Chen
-
Patent number: 8580997Abstract: Disclosed is a process for preparing single enantiomers of beta-amino phenylbutyric acid derivatives and pharmaceutically acceptable salts thereof, which affords the desired compounds having special optical configuration. The process comprises a step of chemical synthesis and a step of resolving the optical isomers of beta-amino phenylbutyric acid derivatives with a resolving agent. The resolving step comprises reacting the optical isomers with resolving agents, such as di-para-toluoyl-L-tartaric acid and di-para-toluoyl-D-tartaric acid. The obtained R-beta-amino phenylbutyric acid derivatives (I) have high optical purity, and the total yield of the accumulative resolution of the laevo and the dextro isomer is up to above 70%.Type: GrantFiled: April 14, 2009Date of Patent: November 12, 2013Assignee: Jiangsu Hengrui Medicine Co. Ltd.Inventors: Piaoyang Sun, Yongjiang Chen, Guangliang Yu
-
Patent number: 8541405Abstract: Methods for the preparation of Ivabradine sulfate and form I crystal thereof. In particular, the Ivabradine sulfate and the preparation methods thereof, and the stable form I crystal of Ivabradine sulfate and the preparation methods thereof.Type: GrantFiled: October 29, 2009Date of Patent: September 24, 2013Assignee: Jiangsu Hengrui Medicine Co., Ltd.Inventors: Piaoyang Sun, Yongjiang Chen, Guangliang Yu
-
Patent number: 8481763Abstract: A process is provided for preparing dronedarone or pharmaceutically acceptable salts thereof. The process comprises reacting 5-amino-2-butyl-3-(4-[3-(dibutylamino)propoxy]benzoyl)benzofuran (compound A) with methanesulfonyl chloride without any catalyst to provide crude dronedarone hydrochloride, which is purified to afford highly pure product. Then, the dronedarone hydrochloride can be converted to highly pure dronedarone through treatment with an alkaline solvent, the dronedarone can be further converted to other pharmaceutically acceptable salts of dronedarone. In this process, acylation between compound A and methanesulfonyl chloride is carried out successfully and the formation of the dimethylsulfonyl by-product is inhibited.Type: GrantFiled: June 3, 2011Date of Patent: July 9, 2013Assignee: Jiangsu Hengrui Medicine Co., Ltd.Inventors: Xianshan Hou, Yongjiang Chen
-
Publication number: 20130072697Abstract: A process is provided for preparing dronedarone or pharmaceutically acceptable salts thereof. The process comprises reacting 5-amino-2-butyl-3-(4-[3-(dibutylamino)propoxy]benzoyl)benzofuran (compound A) with methanesulfonyl chloride without any catalyst to provide crude dronedarone hydrochloride, which is purified to afford highly pure product. Then, the dronedarone hydrochloride can be converted to highly pure dronedarone through treatment with an alkaline solvent, the dronedarone can be further converted to other pharmaceutically acceptable salts of dronedarone. In this process, acylation between compound A and methanesulfonyl chloride is carried out successfully and the formation of the dimethylsulfonyl by-product is inhibited.Type: ApplicationFiled: June 3, 2011Publication date: March 21, 2013Applicant: JIANGSU HENGRUI MEDICINE CO., LTD.Inventors: Xianshan Hou, Yongjiang Chen
-
Patent number: 8362256Abstract: The present invention relates to the salts of N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridine carboxamide, especially hydrochloride and mesylate thereof, and the use of said salts in the preparation of an antineoplastic medicament.Type: GrantFiled: June 11, 2009Date of Patent: January 29, 2013Assignee: Jiangsu Hengrui Medicine Co. Ltd.Inventors: Kaihong Yuan, Piaoyang Sun, Yunshu Zhou, Yongjiang Chen
-
Patent number: 8198485Abstract: A method of resolving an important chemical intermediate, 4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane, comprises the following steps: reacting its two enantiomers of 4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane with di-p-toluoyl-L-tartaric acid (LDTTA) or di-p-toluoyl-D-tartaric acid (DDTTA) in an alcoholic solution or an alcohol in water solution to give the corresponding salts, and then resolving the salts. This method gives high enantiomer excess value, high yield which is more than 80% in total with normal resolution and reverse resolution.Type: GrantFiled: October 10, 2008Date of Patent: June 12, 2012Assignee: Jiangsu Hengrui Medicine Co., Ltd.Inventors: Piaoyang Sun, Yongjiang Chen, Guangliang Yu
-
Publication number: 20120004463Abstract: A method of resolving an important chemical intermediate, 4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane, comprises the following steps: reacting its two enantiomers of 4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane with di-p-toluoyl-L-tartaric acid (LDTTA) or di-p-toluoyl-D-tartaric acid (DDTTA) in an alcoholic solution or an alcohol in water solution to give the corresponding salts, and then resolving the salts. This method gives high enantiomer excess value, high yield which is more than 80% in total with normal resolution and reverse resolution.Type: ApplicationFiled: October 10, 2008Publication date: January 5, 2012Inventors: Piaoyang Sun, Yongjiang Chen, Guangling Yu
-
Publication number: 20110275614Abstract: Methods for the preparation of Ivabradine sulfate and form I crystal thereof. In particular, the Ivabradine sulfate and the preparation methods thereof, and the stable form I crystal of Ivabradine sulfate and the preparation methods thereof.Type: ApplicationFiled: October 29, 2009Publication date: November 10, 2011Inventors: Piaoyang Sun, Yongjiang Chen, Guangliang Yu
-
Publication number: 20110184023Abstract: The present invention relates to the salts of N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl) amino-3-pyridine carboxamide, especially hydrochloride and mesylate thereof, and the use of said salts in the preparation of an antineoplastic medicament.Type: ApplicationFiled: June 11, 2009Publication date: July 28, 2011Applicant: Jiangsu Hengrui Medicine Co., Ltd.Inventors: Kaihong Yuan, Piaoyang Sun, Yunshu Zhou, Yongjiang Chen
-
Publication number: 20110130587Abstract: Disclosed is a process for preparing single enantiomers of beta-amino phenylbutyric acid derivatives and pharmaceutically acceptable salts thereof, which affords the desired compounds having special optical configuration. The process comprises a step of chemical synthesis and a step of resolving the optical isomers of beta-amino phenylbutyric acid derivatives with a resolving agent. The resolving step comprises reacting the optical isomers with resolving agents, such as di-para-toluoyl-L-tartaric acid and di-para-toluoyl-D-tartaric acid. The obtained R-beta-amino phenylbutyric acid derivatives (I) have high optical purity, and the total yield of the accumulative resolution of the laevo and the dextro isomer is up to above 70%.Type: ApplicationFiled: April 14, 2009Publication date: June 2, 2011Applicant: Jiangsu Hengrui Medicine Co., Ltd.Inventors: Piaoyang Sun, Yongjiang Chen, Guangliang Yu